Bayer's Management Shuffle and a Heart Drug Bet Take a Back Seat to the Supreme Court

Bayer shares cling to 200-day MA as U.S. Supreme Court ruling in Durnell could end 65,000 glyphosate lawsuits; Q1 earnings beat but debt swells.

Investors positioning in Bayer have watched the stock dance around a key technical marker in recent sessions. The shares closed Friday at €36.06, barely holding above the 200-day moving average at €35.99. That marginal victory on the chart masks a deeper tension: the stock is down roughly 5% since the start of the year, even as it has clawed back almost 30% over the past twelve months. The real catalyst for direction, however, isn’t found in Leverkusen. It sits in a Washington courtroom.

The U.S. Supreme Court is set to rule by the end of July on Durnell, a case that will decide whether a state can hold a company liable for a product the federal Environmental Protection Agency has declared safe. A victory for Bayer would effectively wipe out the roughly 65,000 outstanding glyphosate lawsuits. CEO Bill Anderson has said he expects to reduce legal risks this year regardless of the outcome, but the size of the potential relief—an end to tens of thousands of claims—has made the ruling the single most important variable for the stock.

While the legal drama plays out, Bayer is pushing ahead with an overhaul of its executive team. The consumer-health division is being restructured to speed up decision-making and lean more heavily on artificial intelligence. Samantha Avivi takes over as global chief marketing officer, Analia de la Fuente moves into the role of global data chief, and Trevor Thrun becomes president of the crucial U.S. market. In investor relations, Jana Marlen Ackermann will take the helm in August 2026, reporting directly to Anderson; her predecessor, Jost Reinhard, is shifting to the pharma division to run the radiology business.

On the operational side, the numbers hold up. First-quarter earnings per share came in at €2.81, and operating profit before special items rose 9%. Revenue exceeded analyst expectations, according to the company. But the balance sheet remains a drag: net debt swelled to over €32.5 billion by the end of March, driven largely by negative free cash flow and around €2 billion in litigation-related outflows during the quarter alone.

In the pipeline, Bayer is pursuing two separate atrial fibrillation programs. One drug candidate, developed in an alliance with the Massachusetts Institute of Technology and Harvard University, has entered a Phase 2 study aimed at restoring normal heart rhythm without the need for electric shocks. A separate compound, designed to regulate electrical activity in the heart, is undergoing a Phase 1 trial. Both are early-stage, and conclusive data is still years away—but they signal the company’s effort to shore up its pharma portfolio amid the legal overhang.

With the Opt-out period for the Roundup class-action settlement now closed, Anderson expects concrete numbers on how many plaintiffs chose to exit the deal in the coming weeks. That data will provide an early gauge of how much legal exposure remains, but the Supreme Court decision will ultimately define the scale of the problem. For now, Bayer’s stock is caught between a promising drug pipeline, a deep management shake-up, and a judicial cliffhanger that could reshape the company’s risk profile overnight.